Shares of Novo Nordisk (NYSE: NVO) are tumbling on Monday, down 5.6% as of 2:11 p.m. ET. The drop comes as the S&P 500 ...

This summary covers recent developments in health, including the sentencing of Terren Peizer for insider trading, Novo Nordisk's drug trial results, new plans from health insurers on authorization ...

Novo Nordisk unveiled its latest data for a weight-loss drug candidate, but shares of the maker of Wegovy and Ozempic tumbled ...

On the Nasdaq, 2,389 stocks rose and 2,026 fell as advancing issues outnumbered decliners by a 1.18-to-1 ratio. The S&P 500 ...

Results from the Phase III REDEFINE 1 trial show that CagriSema led to a 22.7% mean weight reduction at 68 weeks in adults ...

A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase ...

Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments ...

On relatively high volumes, shares in Ryanair slipped by 0.9 per cent to close at €22.90 per share. Jet fuel prices in Europe ...

Novo Nordisk ends partnership with Hims & Hers over compounded Wegovy, shaking the market. See why I recommend a wait-and-see ...

Hims & Hers (HIMS) stock is nosediving after Novo Nordisk (NVO) ended its deal with the company over continued sales of ...

The report spotlights China’s rapid biopharma advancement, alongside a GLP-1 surge, caution surrounding M&A, and a rise in ...

Novo Nordisk's U.S.-listed shares fell more than 5% Monday after the drugmaker revealed the latest results for a new weight-loss treatment.